{"id":"hm15211","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"HM15211 functions as a bispecific antibody designed to target multiple immune regulatory pathways simultaneously, thereby overcoming tumor immune evasion mechanisms. By engaging dual checkpoints, the drug aims to provide enhanced T cell activation and proliferation compared to single-checkpoint inhibitors. This approach is intended to improve anti-tumor immunity in patients with advanced malignancies.","oneSentence":"HM15211 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T cell responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:07:55.394Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors (Phase 2 development)"}]},"trialDetails":[{"nctId":"NCT04505436","phase":"PHASE2","title":"Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2020-07-31","conditions":"NASH - Nonalcoholic Steatohepatitis","enrollment":215},{"nctId":"NCT03374241","phase":"PHASE1","title":"A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2018-04-04","conditions":"Obesity","enrollment":41},{"nctId":"NCT03744182","phase":"PHASE1","title":"A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2018-11-01","conditions":"NAFLD","enrollment":66}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["efocipegtrutide"],"phase":"phase_2","status":"active","brandName":"HM15211","genericName":"HM15211","companyName":"Hanmi Pharmaceutical Company Limited","companyId":"hanmi-pharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HM15211 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T cell responses. Used for Advanced solid tumors (Phase 2 development).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}